Abstract
Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Current Pharmaceutical Design
Title:Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases
Volume: 24 Issue: 26
Author(s): Anna Aiello*, Giuseppina Candore*, Giulia Accardi, Calogero Caruso, Claudia Colomba, Giovanni Duro, Caterina Maria Gambino, Mattia Emanuela Ligotti and Danilo Di Bona
Affiliation:
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Abstract: Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Export Options
About this article
Cite this article as:
Aiello Anna *, Candore Giuseppina*, Accardi Giulia , Caruso Calogero , Colomba Claudia , Duro Giovanni , Gambino Maria Caterina , Ligotti Emanuela Mattia and Di Bona Danilo , Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases, Current Pharmaceutical Design 2018; 24 (26) . https://dx.doi.org/10.2174/1381612824666180911123249
DOI https://dx.doi.org/10.2174/1381612824666180911123249 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Administration of Ethanolic Extract of Ocimum Basilicum Leaves Attenuates Depression like Behavior in the Rats Sensitized by Ovalbumin
Current Nutrition & Food Science Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Current Cancer Therapy Reviews Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design PPARγ and Early Human Placental Development
Current Medicinal Chemistry An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review
Current Drug Metabolism Analytical Methods for Determination of ·NO and ·NO2 and their Applicability in Biological Studies
Current Pharmaceutical Analysis The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology The Relevance of JAK2 in the Regulation of Cellular Transport
Current Medicinal Chemistry Lassa Virus Genome
Current Genomics Location of MBL-Associated Serine Proteases Binding Motifs on Human Mannan-Binding Lectin (MBL)
Protein & Peptide Letters Can Soy Prevent Male Osteoporosis? A Review of the Current Evidence
Current Drug Targets Transforming Growth Factor-β (TGF-β ) and its Role in the Pathogenesis of Systemic Sclerosis: A Novel Target for Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Intracellular Signaling by Phospholipase D as a Therapeutic Target
Current Pharmaceutical Biotechnology Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics
Current Pharmacogenomics Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets